Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer |
Breast Cancer | Phase1 | China France Germany Poland Portugal Spain United States View all |
NCT05870579 |
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS |
Atypical Hemolytic Uremic Syndrome | Phase3 | Brazil China Czechia India View all |
NCT05795140 |
Kesimpta (Ofatumumab) Pregnancy Registry |
Multiple Sclerosis, Pregnancy | United States | NCT05634967 | |
Ribociclib (LEE011) Rollover Study for Continued Access |
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | Phase2 | Taiwan United States |
NCT02934568 |
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors |
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors | United States | NCT05868629 | |
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers |
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer | Phase1 | Belgium Canada France Germany Israel Italy Netherlands Spain Switzerland United States View all |
NCT06562192 |
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study |
Sickle Cell Disease | Phase4 | Lebanon Oman United States |
NCT04657822 |
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | Argentina Austria Brazil Bulgaria Canada China Czechia France Germany Italy Malaysia Mexico Oman Poland Portugal Romania Russia South Korea Spain Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT04877522 |
Asciminib RMP Study |
Chronic Myeloid Leukemia | South Korea | NCT05943522 | |
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea |
Non-Small-Cell Lung Carcinoma | South Korea | NCT05703516 |